At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALNY Alnylam Pharmaceuticals
Market Closed 04-24 16:00:00 EDT
305.54
-8.25
-2.63%
盘后305.54
+0.000.00%
18:46 EDT
High311.10Low302.90Vol825.59K
Open309.63D1 Closing313.79Amplitude2.61%
Mkt Cap40.77BTradable Cap38.55BTotal Shares133.43M
T/O251.96MT/O Rate0.65%Tradable Shares126.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Alnylam Pharmaceuticals revenue is expected to increase by 90.11%, and institutional views are broadly bullish
Earnings Agent  ·  04-23
Earning Preview: Alnylam Pharmaceuticals revenue is expected to increase by 90.11%, and institutional views are broadly bullish
BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-04-24
Reuters  ·  04-25 02:45
BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-04-24
BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-04-17
Reuters  ·  04-18
BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-04-17
BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2026-04-16
Reuters  ·  04-16
BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2026-04-16
Alnylam schedules webcast conference call to discuss first-quarter results
Reuters  ·  04-16
Alnylam schedules webcast conference call to discuss first-quarter results
Alnylam Pharmaceuticals Inc : Leerink Partners Raises Target Price to $362 From $357
THOMSON REUTERS  ·  04-16
Alnylam Pharmaceuticals Inc : Leerink Partners Raises Target Price to $362 From $357
U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services
Reuters  ·  04-16
U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY) and Apellis Pharmaceuticals (APLS)
TIPRANKS  ·  04-15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY) and Apellis Pharmaceuticals (APLS)
Alnylam Pharmaceuticals Is Maintained at Buy by Truist Securities
Dow Jones  ·  04-14
Alnylam Pharmaceuticals Is Maintained at Buy by Truist Securities
Alnylam Pharmaceuticals Inc : Truist Securities Cuts Target Price to $505 From $515
THOMSON REUTERS  ·  04-13
Alnylam Pharmaceuticals Inc : Truist Securities Cuts Target Price to $505 From $515
U.S. RESEARCH ROUNDUP-Chevron, Ford, Occidental Petroleum
Reuters  ·  04-13
U.S. RESEARCH ROUNDUP-Chevron, Ford, Occidental Petroleum
Alnylam CHRO Melissa McLaughlin disposes of common shares worth $1,003,169.76
Reuters  ·  04-08
Alnylam CHRO Melissa McLaughlin disposes of common shares worth $1,003,169.76
BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-04-07
Reuters  ·  04-08
BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-04-07
How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors
Simply Wall St.  ·  04-07
How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors
An S&P 500 change may be imminent. These stocks are leading contenders to join the index.
Dow Jones  ·  04-07
An S&P 500 change may be imminent. These stocks are leading contenders to join the index.
Genmab names Margarida Duarte general manager for Europe and emerging markets
Reuters  ·  04-01
Genmab names Margarida Duarte general manager for Europe and emerging markets
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
TIPRANKS  ·  03-31
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial
Reuters  ·  03-31
Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial
3 Stocks That May Be Trading Up To 43.2% Below Intrinsic Value Estimates
Simply Wall St.  ·  03-30
3 Stocks That May Be Trading Up To 43.2% Below Intrinsic Value Estimates
Alnylam Pharmaceuticals Price Target Maintained With a $510.00/Share by HC Wainwright & Co.
Dow Jones  ·  03-26
Alnylam Pharmaceuticals Price Target Maintained With a $510.00/Share by HC Wainwright & Co.

Introduction

Company Name.
Alnylam Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Issue price:
--